No Data
No Data
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91
JMP Securities analyst Jonathan Wolleben maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $91.According to TipRanks data, the analyst has a success
Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Armata Pharmaceuticals (ARMP)
Pfizer Signals Progress on Obesity Pill, Boosting Stock
By Ciara Linnane and Eleanor Laise Oral versions of popular weight-loss drugs could be cheaper, more accessible, analysts say Pfizer Inc.'s stock (PFE) rose 2.8% early Thursday, after the drug
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
No Data